About Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Clinical Trials at Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica
During the past decade, Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 2 clinical trials were completed, i.e. on
average, 22.2% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica"
#1 collaborator was "Pierre Fabre Laboratories" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 1 trials.
Clinical Trials Conditions at Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica
According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica" are
"Solid Tumors" (3 trials), "Malignant Melanoma" (2 trials), "Cancer" (1 trials), "Melanoma" (1 trials) and "Renal Cell Carcinoma" (1 trials). Many other conditions were trialed in "Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica" in a lesser frequency.
Clinical Trials Intervention Types at Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica
Most popular intervention types in "Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica" are "Drug" (8 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (4 trials), "RO6958688" (2 trials), "Alectinib" (1 trials), "Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody" (1 trials) and "Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica
The vast majority of trials in "Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica" are
10 trials for "All" genders.
Clinical Trials Status at Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica
Currently, there are NaN active trials in "Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica".
undefined are not yet recruiting,
1 are recruiting,
2 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 6 completed trials in Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica, 3 "Phase 1"
clinical trials were conducted, 3 "Phase 2" clinical
trials and 1 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 0 trials that are defined as “Not Applicable".